MedTrace Logo

Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer

NCT06504875 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 23

Last updated 2024-07-17

No results posted yet for this study

Summary

The objective is to evaluate whether the neoadjuvant combination of PD-1 inhibitor tislelizumab and interleukin-2 (IL-2) can significantly enhance the complete response rate (cCR + local excision pCR) and organ preservation rate in patients with MSS/pMMR locally advanced rectal cancer.

Conditions

Interventions

DRUG

Tislelizumab

Tislelizumab 200mg ivd D1

DRUG

Interleukin-2

Interleukin 2 100IU HD,QOD d1-d14

DRUG

Capecitabine

Capecitabine: 1000mg/m2 bid po, d1-d14

DRUG

Oxaliplatin

Oxaliplatin 130mg/m2 ivd, d1

Sponsors & Collaborators

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-10
Primary Completion
2025-07-10
Completion
2027-07-10

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06504875 on ClinicalTrials.gov